AXP vs BBOT · P/E 20, rev $21.73B vs rev $7.5M
American Express Company (AXP) versus BridgeBio Oncology Therapeutics, Inc. (BBOT) — a side-by-side from cached financials, not a winner call.
American Express Company (AXP) is a credit services company listed on US.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Latest reported AXP revenue for 2026-06-30 was $21.73B. Net income was $6.08B. AXP currently screens at market cap $215.94B and trailing P/E 19.8.
Latest reported BBOT revenue for 2026-06-30 was $7.5M. Net income was -$98.6M. Revenue was up 90.0% from 2026-03-31 to 2026-06-30. BBOT currently screens at market cap $610.4M.
AXP currently screens at market cap $215.94B and trailing P/E 19.8. BBOT currently screens at market cap $610.4M.
Not investment advice. Open the AXP and BBOT stock pages for the full models.
Not investment advice.